ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
July 28 2021 - 4:56PM
Business Wire
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company leading the development of novel antibody
drug conjugates (ADCs) to treat hematological malignancies and
solid tumors, today announced that it will host a conference call
and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. EDT to
report financial results for the second quarter 2021 and provide
business updates.
To access the live call, please dial 833-303-1198 (domestic) or
+1 914-987-7415 (international) and provide confirmation number
6962756. A live webcast of the presentation will be available under
“Events and Presentations” in the Investors section of the ADC
Therapeutics website at ir.adctherapeutics.com. The archived
webcast will be available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of cancer patients with
its next-generation, targeted antibody drug conjugates (ADCs). The
Company is advancing its proprietary PBD-based ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large B-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, the Company has
multiple PBD-based ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA™ is a trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210728006046/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com Tel.: +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com Tel.: +1 917 288 7023
EU Media Alexandre Müller Dynamics Group
amu@dynamicsgroup.ch Tel: +41 (0) 43 268 3231
USA Media Annie Starr 6 Degrees astarr@6degreespr.com
Tel.: +1 973-768-2170
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2024 to May 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From May 2023 to May 2024